JMP Securities Reiterates a Buy Rating on Agenus Inc.By Ryan Adsit
According to TipRanks.com, King is a 1-star analyst with an average return of -1.3% and a 42.7% success rate. King covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Syndax Pharmaceuticals Inc, and Karyopharm Therapeutics.
Agenus Inc. has an analyst consensus of Moderate Buy.
Based on Agenus Inc.’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $4.45 million and GAAP net loss of $40.77 million. In comparison, last year the company earned revenue of $6.85 million and had a GAAP net loss of $13.12 million.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGEN in relation to earlier this year.
Agenus, Inc. is a biotechnology company, which is focused on the development and commercialization of technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its core technology portfolio consists of Saponin platform and Heat Shock Protein platform. The company within its Saponin Platform is QS-21 Stimulon adjuvant, or QS-21 Stimulon, which is used by its licensees in numerous vaccines under development in clinical trials, some as advanced as phase 3, for a variety of diseases, including cancer, shingles, malaria, Alzheimer’s disease, human immunodeficiency virus and tuberculosis. Agenus within its HSP Platform is developing its recombinant series and prophage series vaccines. The company’s HerpV, a therapeutic vaccine candidate from the recombinant series, which contains QS-21 Stimulon, has been tested in a phase 1 clinical trial for the treatment of genital herpes. Agenus was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.